1. Cell Cycle/DNA Damage
    Epigenetics
  2. Aurora Kinase
  3. AZD1152

AZD1152 (Synonyms: Barasertib)

Cat. No.: HY-10127 Purity: 99.62%
Handling Instructions

AZD1152 is a pro-drug of Barasertib-hQPA, which is a highly selective Aurora B inhibitor with IC50 of 0.37 nM in a cell-free assay.

For research use only. We do not sell to patients.

AZD1152 Chemical Structure

AZD1152 Chemical Structure

CAS No. : 722543-31-9

Size Price Stock Quantity
Free Sample (0.5-1 mg)   Apply now  
10 mM * 1 mL in DMSO USD 186 In-stock
Estimated Time of Arrival: December 31
5 mg USD 144 In-stock
Estimated Time of Arrival: December 31
10 mg USD 240 In-stock
Estimated Time of Arrival: December 31
50 mg USD 984 In-stock
Estimated Time of Arrival: December 31
100 mg   Get quote  
200 mg   Get quote  

* Please select Quantity before adding items.

Customer Review

Based on 5 publication(s) in Google Scholar

Other Forms of AZD1152:

Top Publications Citing Use of Products

View All Aurora Kinase Isoform Specific Products:

  • Biological Activity

  • Protocol

  • Purity & Documentation

  • References

  • Customer Review

Description

AZD1152 is a pro-drug of Barasertib-hQPA, which is a highly selective Aurora B inhibitor with IC50 of 0.37 nM in a cell-free assay.

IC50 & Target

IC50: 0.37 nM (Aurora B)

In Vitro

AZD1152 displays >3000-fold selectivity for Aurora B as compared with Aurora A which has an IC50 of 1.368 μM. AZD1152 has even less activity against 50 other serine-threonine and tyrosine kinases including FLT3, JAK2, and Abl. AZD1152 inhibits the proliferation of hematopoietic malignant cells such as HL-60, NB4, MOLM13, PALL-1, PALL-2, MV4-11, EOL-1, THP-1, and K562 cells with IC50 of 3-40 nM, displaying appr 100-fold potency than another Aurora kinase inhibitor ZM334739 which has IC50 of 3-30 μM. AZD1152 inhibits the clonogenic growth of MOLM13 and MV4-11 cells with IC50 of 1 nM and 2.8 nM, respectively, as well as the freshly isolated imatinib-resistant leukemia cells with IC50 values of 1-3 nM, more significantly compared with bone marrow mononuclear cells with IC50 values of >10 nM. AZD1152 induces accumulation of cells with 4N/8N DNA content, followed by apoptosis in a dose- and time-dependent manner[1]. AZD1152 causes significant accumulation of cells with 4N/8N DNA content in KMS12 and U266 and induces apoptosis in KMS18 and U266. AZD1152 in combination with DEX, has negative effects on cell viability in comparison with single agent in PMI8226, KMS11 and U266[3].

In Vivo

Administration of AZD1152 (25 mg/kg) alone markedly suppresses the growth of MOLM13 xenografts, confirmed by the observation of necrotic tissue with infiltration of phagocytic cells[1]. In addition, AZD1152 (10-150 mg/kg/day) significantly inhibits the growth of a variety of human solid tumor xenografts, including colon, breast, and lung cancers, in a dose-dependent manner[2]. AZD1152 (25 mg/kg/day) treatment reduces xenograft levels such that they are slightly lower levels than after the first round of treatment, but this is not statistically significant indicating that residual cells might be more resistant to a second cycle of AZD1152[4].

Clinical Trial
Molecular Weight

587.54

Formula

C₂₆H₃₁FN₇O₆P

CAS No.

722543-31-9

SMILES

O=C(NC1=CC=CC(F)=C1)CC2=CC(NC3=C4C=CC(OCCCN(CC)CCOP(O)(O)=O)=CC4=NC=N3)=NN2

Shipping

Room temperature in continental US; may vary elsewhere

Storage
Powder -20°C 3 years
  4°C 2 years
In solvent -80°C 6 months
  -20°C 1 month
Solvent & Solubility
In Vitro: 

DMSO : ≥ 33 mg/mL (56.17 mM)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 1.7020 mL 8.5101 mL 17.0201 mL
5 mM 0.3404 mL 1.7020 mL 3.4040 mL
10 mM 0.1702 mL 0.8510 mL 1.7020 mL
*Please refer to the solubility information to select the appropriate solvent.
In Vivo:
  • 1.

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.17 mg/mL (3.69 mM); Clear solution

  • 2.

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.17 mg/mL (3.69 mM); Clear solution

  • 3.

    Add each solvent one by one:  10% DMSO    90% corn oil

    Solubility: ≥ 2.17 mg/mL (3.69 mM); Clear solution

*All of the co-solvents are provided by MCE.
References
Cell Assay
[3]

Approximately 1×105 cells in RPMI media with 10% FBS media are plated per well in a treated 96-well plate at 24-h intervals for up to 120 h (in triplicate for each time-point). For each timepoint, 20 μL of MTS reagent [3-(4,5-dimethylthiazol-2-yl)-5- (3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2Htetrazolium, inner salt] solution is added to each well and incubated at 37°C for 4 h. The plate absorbance is read at 490 nm on a 96-well spectra max 190 Plate Reader using Softmax Pro 4.8 Software. MTS solution is added to media-only wells to correct for background. Setting the control cells at 100% viability, the viability of cells treated with various concentrations of siRNA or drug is determined and graphed using MS Excel.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration
[1]

Female immune-deficient BALB/c nude mice at 4 weeks of age are purchased from JAPAN SLC and are maintained in pathogen-free conditions with irradiated chow. Animals are bilaterally, subcutaneously injected with 2×106 MOLM13 cells/tumor in 0.1 mL Matrigel. When MOLM13 cells formed palpable tumors, mice are divided randomLy into control (n=5) and treatment groups (n=5), and treatment is begun. AZD1152 (5 or 25 mg/kg) with or without vincristine (0.2 mg/kg) is given to mice by intraperitoneal injection 4 times a week or every another day, respectively. Daunorubicin (1 mg/kg) is given to mice by intraperitoneal injection 6 times during 2 weeks of treatment either alone or in combination with AZD1152 (5 mg/kg). The dose of these agents is determined by our preliminary studies. Control diluent is given to the untreated control mice. Body weight and tumors are measured twice a week. Tumor sizes are calculated. At the end of the experiment, animals are killed by CO2 asphyxiation and tumor weights are measured after their careful resection. Tumor tissue is collected for analysis.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

References

Purity: 99.62%

  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2

Inquiry Online

Your information is safe with us. * Required Fields.

Product name

 

Salutation

Applicant name *

 

Email address *

Phone number *

 

Organization name *

Country or Region *

 

Requested quantity *

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
AZD1152
Cat. No.:
HY-10127
Quantity: